False-positive carbapenem-hydrolyzing confirmatory tests due to ACT-28, a chromosomally encoded AmpC with weak carbapenemase activity from enterobacter kobei

23Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In Enterobacter cloacae complex (ECC), the overproduction of the chromosome-encoded cephalosporinase (cAmpC) associated with decreased outer membrane permeability may result in carbapenem resistance. In this study, we have characterized ACT-28, a cAmpC with weak carbapenemase activity, from a single Enterobacter kobei lineage. ECC clinical isolates were characterized by whole-genome sequencing (WGS), susceptibility testing, and MIC, and carbapenemase activity was monitored using diverse carbapenem hydrolysis methods. ACT-28 steady-state kinetic parameters were determined. Among 1,039 non-carbapenemase-producing ECC isolates with decreased susceptibility to carbapenems received in 2016-2017 at the French National Reference Center for antibiotic resistance, only 8 had a positive carbapenemase detection test (Carba NP). These eight ECC isolates were resistant to broad-spectrum cephalosporins due to AmpC derepression, showed decreased susceptibility to carbapenems, and were categorized as carbapenemase-producing Enterobacteriaceae (CPE) according to several carbapenemase detection assays. WGS identified a single clone of E. kobei ST125 expressing only its cAmpC, ACT-28. The blaACT-28 gene was expressed in a wild-type and in a porin-deficient Escherichia coli background and compared to the blaACT-1 gene. Detection of carbapenemase activity was positive only for E. coli expressing the blaACT-28 gene. Kinetic parameters of purified ACT-28 revealed a slightly increased imipenem hydrolysis compared to that of ACT-1. In silico porin analysis revealed the presence of a peculiar OmpC-like protein specific to E. kobei ST125 that could impair carbapenem influx into the periplasm and thus enhance carbapenem-resistance caused by ACT-28. We described a widespread lineage of E. kobei ST125 producing ACT-28, with weak carbapenemase activity that can lead to false-positive detection by several biochemical and phenotypic diagnostic tests.

References Powered by Scopus

Identification of acquired antimicrobial resistance genes

3878Citations
N/AReaders
Get full text

DNA-DNA hybridization values and their relationship to whole-genome sequence similarities

3751Citations
N/AReaders
Get full text

Updated functional classification of β-lactamases

1837Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The current burden of carbapenemases: Review of significant properties and dissemination among gram-negative bacteria

152Citations
N/AReaders
Get full text

Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales

53Citations
N/AReaders
Get full text

Class C b-Lactamases: Molecular Characteristics

31Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Jousset, A. B., Oueslati, S., Bernabeu, S., Takissian, J., Creton, E., Vogel, A., … Naas, T. (2019). False-positive carbapenem-hydrolyzing confirmatory tests due to ACT-28, a chromosomally encoded AmpC with weak carbapenemase activity from enterobacter kobei. Antimicrobial Agents and Chemotherapy, 63(5). https://doi.org/10.1128/AAC.02388-18

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

52%

Researcher 7

33%

Lecturer / Post doc 2

10%

Professor / Associate Prof. 1

5%

Readers' Discipline

Tooltip

Immunology and Microbiology 8

35%

Biochemistry, Genetics and Molecular Bi... 7

30%

Agricultural and Biological Sciences 5

22%

Medicine and Dentistry 3

13%

Save time finding and organizing research with Mendeley

Sign up for free